IMG-7289 in Patients With Myelofibrosis

• Status: Active, not recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis.

This study investigates the following:

• The safety and tolerability of IMG-7289

• The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only)

• The pharmacodynamic effect of IMG-7289

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imago BioSciences,Inc.

Criteria

Inclusion Criteria:

• >18 years

• Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT

• High or intermediate-2 risk disease, as defined per protocol

Exclusion Criteria:

• Receiving other treatments for the condition (with exceptions and time limits)

• Major surgery in last 4 weeks, minor surgery in the last 2 weeks

• History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening

• History of splenectomy

• Current use of prohibited medications

• A concurrent second active and nonstable malignancy

• Known HIV infection or active Hepatitis B or Hepatitis C virus infection

• Other hematologic/biochemistry requirements, as per protocol

• Use of investigational agent within last 14 days

• Pregnant or lactating females